Early Clinical
Early phase development services that will enable informed decision making for your drug development programme.
Innovative early clinical solutions that will advance your drug development strategy
-
6
Clinical research units across Europe and the USA -
894
Early phase clinical trials over the last 5 years -
32,600
Healthy volunteers and patients targeted
ICON is committed to the highest standards of excellence and scientific expertise in early clinical drug development.
Our early clinical services deliver full visibility and control to meet the requirements of increasingly complex clinical trial requirements. A dedicated team of early phase specialists engage with you to develop a trial that is best for your compound. Together we will build a tailored approach that leverages our asset development consulting, clinical pharmacology expertise, extensive research facilities, early phase operational experience, and biometrics capabilities to conduct your trial within both healthy volunteers and patient populations.
We deliver a range of early clinical studies including:
|
|
|
- Asset Development Consulting In-depth scientific expertise across disciplines.
- Biotech Helping biotech meet critical milestones
- Clinical Pharmacology We help design a protocol that works harder and smarter for you.
- Accelerated Pharmaceutical Solutions A one stop drug development solution that is perfectly suited for early phase trials with shorter timelines.
- Bioanalytical and Biomarker Laboratories Supporting rapid in-house simple analysis with method development, assay validation and specimen analysis.
- Clinical Research Units Network of ICON-owned clinics with the ability to deliver the most complex of healthy volunteer, patient, or hybrid first-in-human and proof-of-concept studies.
- Biometrics Specialised data management, programming, biostatistics and medical writing services
- Early Phase Patient Studies Customised solutions designed to evaluate clinical endpoints and biomarkers within a smaller sample of patients to provide you with reliable proof of concept data.
- Quantitative Pharmacology and Pharmacometrics Expert clinical and nonclinical pharmacokinetic, pharmacodynamic, and exposure response data analysis services.
- Healthy Volunteer Recruitment Flexible volunteer recruitment solutions designed to serve the needs of your early phase clinical trial.
Asset Development Consulting
In-depth scientific expertise across disciplines.
Biotech
Helping biotech meet critical milestones
Clinical Pharmacology
We help design a protocol that works harder and smarter for you.
Accelerated Pharmaceutical Solutions
A one stop drug development solution that is perfectly suited for early phase trials with shorter timelines.
Bioanalytical and Biomarker Laboratories
Supporting rapid in-house simple analysis with method development, assay validation and specimen analysis.
Clinical Research Units
Network of ICON-owned clinics with the ability to deliver the most complex of healthy volunteer, patient, or hybrid first-in-human and proof-of-concept studies.
Biometrics
Specialised data management, programming, biostatistics and medical writing services
Early Phase Patient Studies
Customised solutions designed to evaluate clinical endpoints and biomarkers within a smaller sample of patients to provide you with reliable proof of concept data.
Quantitative Pharmacology and Pharmacometrics
Expert clinical and nonclinical pharmacokinetic, pharmacodynamic, and exposure response data analysis services.
Healthy Volunteer Recruitment
Flexible volunteer recruitment solutions designed to serve the needs of your early phase clinical trial.
An independent 2025 ISR benchmarking report has ranked ICON as one of the top-performing CROs in Phase 1 clinical trial services. ICON leads the average performance score of other large CROs in all 17 operational metrics, with a significant lead differential in 14.
We outperformed the phase 1 industry average for all metrics, receiving our highest performance ratings on 'Easy to work with', 'Meeting overall project timelines' and 'Technology for real-time access to data'. Overall satisfaction with ICON for Phase 1 services has remained at last year’s all-time high and is the highest of all large CROs. This consistent, industry-leading performance reflects our strong commitment to excellence in early phase clinical research. Read more in the press release.
Our dedicated early clinical experts have the experience to address the most demanding early phase drug development challenges including:
Increasing complexity of trials
Delivery of reliable safety and efficacy data faster
Finding the right clinical settings to support complex assessment
Early phase challenges for biotechs
This whitepaper explores the growing challenges facing biotech during early phase drug development, and how these can be navigated to ensure the best possible outcomes.
_1.jpeg?crop=yes&w=2048&h=1251&a=0,0&itok=0zEYY1fc "survey report"){kind=icon}
ICON survey report: Early phase development - understanding key obstacles for biotechs in 2024
ICON conducted a survey of 149 small and medium biotechs to understand the challenges they are currently experiencing in early phase drug development.